If you want to know where obesity is headed in the near term, pay attention to one word: amylin.

We have been following Zealand Pharma’s petrelintide for years, so the drug itself is not the story today. What is changing is the conversation around it, because amylin is rapidly moving from an interesting alternative mechanism to one of the most important …